Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 12 years and older inclusive of either sex.~2. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit \[Visit 1\]) with exacerbations (clinical evidence of active symptoms) during the spring allergy season (tree/grass pollen)~3. A 12-hour reflective TNSS ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for the AM assessment at the Screening Visit (Visit 1).~Exclusion Criteria:~1. Pregnant or lactating women.~2. Plans to travel outside the known pollen area for the investigative site for \> 24 hours during the last 7 days of run in period.~3. History of anaphylaxis and/or other severe local reaction(s) to skin testing.~4. History of positive test for HIV, Hepatitis B or Hepatitis C infection.~5. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.~6. Subjects with an active pulmonary disorder or infection.~7. Subjects with posterior subcapsular cataracts or glaucoma

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSP 301 NS (Type: EXPERIMENTAL): None
- Olopatadine HCl NS (Type: ACTIVE_COMPARATOR): None
- Mometasone furoate NS (Type: ACTIVE_COMPARATOR): None
- GSP 301 Placebo NS (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).